|
NICHD-Maternal and Child Health (MCH) Electronic Health Record (EHR)
|
Research Initiative
|
HRSA
|
NICHD
|
This Interdepartmental Delegation Authority (IDDA) provides funds for the Maternal and Child Health (MCH) Electronic Health Record (EHR) Pediatric Practice Based Research Network (PBRN) Initiative.
|
|
Nicotine Research Cigarettes (SPECTRUM)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIDA
|
This partnership with the Food and Drug Administration (FDA) is for the production of produce research cigarettes.
|
|
NIEHS Patterns of Co-Exposure in Danish Women of Reproductive Age
|
Research Initiative
|
CDC
|
NIEHS
|
This study characterizes exposure to National Health and Nutrition Examination Survey (NHANES) chemicals in a set of 50 Danish women participating in a time to pregnancy study that will also include follow-up of offspring.
|
|
NIH / FDA interagency partnership to foster tobacco regulatory research
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIDA
|
Trans-NIH collaborative effort with the FDA''s Center for Tobacco Products to conduct research to support its regulatory activities over tobacco products.
|
|
NIH Biomarkers Consortium
|
Research Initiative
|
CMS, FDA
|
NIMH, NCI, NHLBI, NIA, NIAID, NIAMS, NIBIB, NICHD, NIDDK, NINDS
|
The Biomarkers Consortium develops, validates, and qualifies biological markers (biomarkers) to speed the development of medicines and therapies for detection, prevention, diagnosis, and treatment of disease and improve patient care. The NIH Public Private Partnership Program coordinates NIH participation in the sponsored Biomarkers Foundation for the National Institutes of Health (FNIH) consortium. The consortium is an umbrella which encompasses research projects, ongoing working groups, as well as occasional workshops and conferences.
|
|
NIH Guide for Grants and Contracts
|
Resource Development
|
AHRQ, CDC, FDA
|
OD/OER, CC, CIT, CSR, FIC, NCATS, NCCAM, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI
|
The National Institutes of Health (NIH) Guide for Grants and Contracts is the official publication for NIH medical and behavioral grant policies, guidelines, and funding opportunities, and is used by other U. S. Department of Health and Human Services (HHS) agencies to disseminate Funding Opportunity Announcements (FOAs) to its 50,000 subscribers.
|
|
NIH Loan Repayment Programs Communications and Outreach Project
|
Committee, Work group, Advisory group, or Task Force
|
HRSA
|
OD/OER, NCI, NHLBI, NIA, NIAID, NIAMS, NICHD, NIDA, NIDCR, NIMH, NIMHD
|
The NIH Loan Repayment Programs (LRP) Communications and Outreach Project was initiated to form collaborative outreach relationships with LRP IC-stakeholders and their Communications Officers. The goal of this activity was to combine communications resources, share informational materials, and coordinate messaging strategies and timing to promote the LRPs. The Division of Loan Repayment (DLR) met with each participating IC as well as other Federal Agencies to learn about their successes, and the needs of each participating IC were identified. A comprehensive strategy was designed and, during FY 2014, participating ICs implemented this strategy. The net effect of this collaborative effort was a reversal in the downward trend of applications to the Program and a further enrichment of the LRP application pool.
|
|
NIH Recombinant DNA Advisory Committee
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NCI, NHGRI, NIAID, NINDS
|
The Recombinant DNA Advisory Committee (RAC) advises the National Institutes of Health on the safe and ethical conduct of basic and clinical research involving recombinant DNA. It reviews protocols and provides recommendations for each protocol to enhance the scientific and ethical design. The RAC also discusses safety data and other emerging issues for the field of gene therapy. This year the RAC hosted a meeting to develop biosafety guidelines for gain-of-function research with H5N1 which led to the amendment of the NIH Guidelines for Research with Synthetic and Recombinant Research. The RAC also hosted a meeting of mid-level investigators to examine the scientific and other challenges that gene therapy will face in the next decade and a meeting to discuss optimization of the design of clinical trials using gene modified T cells in order to realize the potential of this immunotherapy while minimizing the risk to subjects.
|
|
NIH Translational Research Interest Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI, CC, CIT, CSR, NCATS, NCCAM, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI, OD/OER, OD/OIR, OD/OSP
|
As Chair of the National Institutes of Health (NIH) Translational Research Interest Group (TRIG), the National Cancer Institute (NCI) staff has coordinated Forums, Workshops, NIH Bench-to-Bedside Awardees’ Lecture Series, and Monthly Seminar Series to help bridge the gap between laboratory research and clinical applications; suggestions of topics and speakers for the Annual NIH Research Festivals; and nominations of speakers for the NIH Wednesday Afternoon Lecture Series and the NIH Director’s Lecture Series. NCI staff has informed TRIG members of scientific events coordinated with other NIH Scientific Interest Groups and Working Groups.
|
|
NIH-CDC-IDSA Guidelines for Treatment of HIV Related Opportunistic Infections Among Adults and Adolescents
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
CC
|
The National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, and the Centers for Disease Control and Prevention (CDC) have developed guidelines for treatment of opportunistic infections (OIs) among adults and adolescents infected with human immunodeficiency virus (HIV). These guidelines are intended for clinicians and other health-care providers who care for HIV-infected adults and adolescents, including pregnant women; they complement companion guidelines for treatment of OIs among HIV-infected children and previously published guidelines for prevention of OIs in these populations.
|